Cipla unveils its new point-of-care molecular diagnostic device

INDIA – Indian pharma major Cipla Limited (Cipla) has expanded its product portfolio with the launch of its new point-of-care medical testing device christened Cippoint designed to be a direct aid in clinical-decision making.

In a press release, the drugmaker said: “Cippoint offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers.”

Cipla pointed out that its state-of-the-art device is an immunofluorescence-based quantitative analyser that will allow healthcare professionals to identify DNA or RNA targets in 3-15 minutes to support them in generating accurate, reliable and timely data.

Moreover, the Mumbai-based pharmaceutical company stated that its new medical testing product will be retailed at affordable prices in India in an effort to bridge the current gap in the diagnostic ecosystem across the region.

Cipla reassured healthcare professionals that its easy-to-use device for molecular diagnostics can be used in rural areas, mobile vans, and remote areas with limited infrastructure thus enhancing the patient experience while delivering patient-centered care.

“Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience, ultimately improving patient health outcomes,” the company highlighted.

Cipla confirmed that its point- of-care testing device is CE IVD approved – indicating the device is approved by the European In-Vitro Diagnostic Device Directive – thus ensuring reliable testing solutions.

In addition, the regulatory approval means that Cipla’s point-of-care molecular diagnostic device for infectious diseases may be legally commercialized in the European Union for use as a clinical diagnostic by pathology laboratories.

Commenting on the launch of Cippoint, Chief Executive Officer (CEO) of One India Business Mr. Achin Gupta acknowledged that Cipla has always been at the forefront of addressing the global diseases burden.

“We are actively working towards delivering innovative solutions that enable prompt and effective diagnosis, thereby plugging gaps in the diagnostic ecosystem,” he stated.

Mr. Gupta underscored that with the launch of Cippoint further strengthens the Company’s vision of supporting patients across the healthcare continuum.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.